Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Prelude Therapeutics Inc (PRLD) since 2020 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Prelude Therapeutics Inc. Table 2 shows the detailed insider transactions. This company's CIK number is 1678660.
Total stock buying since 2020: $88,332,308.
Total stock sales since 2020: $10,265,426.
Total stock option exercises since 2020: $1,408,634.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 892,916 | $621,512 | 0 | $0 | 28,125 | $0 |
| 2024 | 131,888 | $121,966 | 0 | $0 | 37,500 | $0 |
| 2023 | 1,760,286 | $10,116,971 | 13,280 | $81,273 | 56,250 | $0 |
| 2022 | 20,000 | $89,900 | 0 | $0 | 36,062 | $68,157 |
| 2021 | 8,000 | $94,880 | 320,519 | $10,184,153 | 309,867 | $1,340,477 |
| 2020 | 4,067,741 | $77,287,079 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-07 | 0 | $0 | 0 | $0 | 9,375 | $0 |
| 2025-04 | 0 | $0 | 0 | $0 | 9,375 | $0 |
| 2025-03 | 892,916 | $621,512 | 0 | $0 | 0 | $0 |
| 2025-01 | 0 | $0 | 0 | $0 | 9,375 | $0 |
| 2024-12 | 131,888 | $121,966 | 0 | $0 | 0 | $0 |
| 2024-10 | 0 | $0 | 0 | $0 | 9,375 | $0 |
| 2024-07 | 0 | $0 | 0 | $0 | 9,375 | $0 |
| 2024-04 | 0 | $0 | 0 | $0 | 9,375 | $0 |
| 2024-01 | 0 | $0 | 0 | $0 | 9,375 | $0 |
| 2023-10 | 0 | $0 | 0 | $0 | 9,375 | $0 |
| 2023-07 | 0 | $0 | 0 | $0 | 9,375 | $0 |
| 2023-05 | 1,760,286 | $10,116,971 | 0 | $0 | 0 | $0 |
| 2023-04 | 0 | $0 | 13,280 | $81,273 | 37,500 | $0 |
| 2022-12 | 10,000 | $47,600 | 0 | $0 | 0 | $0 |
| 2022-06 | 10,000 | $42,300 | 0 | $0 | 0 | $0 |
| 2022-03 | 0 | $0 | 0 | $0 | 36,062 | $68,157 |
| 2021-12 | 8,000 | $94,880 | 28,751 | $373,763 | 28,751 | $211,894 |
| 2021-11 | 0 | $0 | 28,751 | $464,271 | 28,751 | $369,450 |
| 2021-10 | 0 | $0 | 15,000 | $468,120 | 15,000 | $28,350 |
| 2021-09 | 0 | $0 | 32,000 | $1,257,522 | 32,000 | $246,800 |
| 2021-08 | 0 | $0 | 33,333 | $1,107,039 | 33,333 | $58,924 |
| 2021-07 | 0 | $0 | 35,000 | $1,136,080 | 35,000 | $56,950 |
| 2021-06 | 0 | $0 | 15,000 | $473,535 | 15,000 | $28,350 |
| 2021-05 | 0 | $0 | 33,333 | $1,304,488 | 33,333 | $58,399 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-07-04 | Huang Jane (President, CMO) | Option Ex | 9,375 | .00 | 0 |
| 2025-04-04 | Huang Jane (President, CMO) | Option Ex | 9,375 | .00 | 0 |
| 2025-03-25 | Combs Andrew (Chief Chemistry Officer) | Buy | 100,000 | .69 | 69,300 |
| 2025-03-25 | Vaddi Krishna (CEO) | Buy | 675,000 | .69 | 467,774 |
| 2025-03-21 | Vaddi Krishna (CEO) | Buy | 15,000 | .73 | 10,965 |
| 2025-03-20 | Vaddi Krishna (CEO) | Buy | 5,416 | .73 | 3,948 |
| 2025-03-13 | Vaddi Krishna (CEO) | Buy | 50,000 | .72 | 35,800 |
| 2025-03-12 | Vaddi Krishna (CEO) | Buy | 47,500 | .71 | 33,725 |
| 2025-01-04 | Huang Jane (President, CMO) | Option Ex | 9,375 | .00 | 0 |
| 2024-12-19 | Vaddi Krishna (CEO) | Buy | 6,888 | .89 | 6,116 |
| 2024-12-19 | Lim Bryant David (CLO, Interim CFO, Corp Sec.) | Buy | 25,000 | .91 | 22,650 |
| 2024-12-18 | Vaddi Krishna (CEO) | Buy | 100,000 | .93 | 93,200 |
| 2024-10-04 | Huang Jane (President, CMO) | Option Ex | 9,375 | .00 | 0 |
| 2024-07-04 | Huang Jane (President, CMO) | Option Ex | 9,375 | .00 | 0 |
| 2024-04-04 | Huang Jane (President, CMO) | Option Ex | 9,375 | .00 | 0 |
| 2024-01-04 | Huang Jane (President, CMO) | Option Ex | 9,375 | .00 | 0 |
| 2023-10-04 | Huang Jane (President, CMO) | Option Ex | 9,375 | .00 | 0 |
| 2023-07-04 | Huang Jane (President, CMO) | Option Ex | 9,375 | .00 | 0 |
| 2023-05-25 | Vaddi Krishna (CEO) | Buy | 900 | 5.31 | 4,779 |
| 2023-05-24 | Vaddi Krishna (CEO) | Buy | 1,000 | 5.01 | 5,011 |
| 2023-05-24 | Lim Bryant David (Chief Legal Officer, Corp Sec.) | Buy | 2,400 | 5.39 | 12,936 |
| 2023-05-23 | Vaddi Krishna (CEO) | Buy | 11,856 | 5.63 | 66,749 |
| 2023-05-23 | Chardonnet Laurent (Chief Financial Officer) | Buy | 5,000 | 5.50 | 27,500 |
| 2023-05-22 | Bonita David P | Buy | 869,565 | 5.75 | 4,999,998 |
| 2023-05-22 | Orbimed Capital Llc | Buy | 869,565 | 5.75 | 4,999,998 |
| 2023-04-06 | Huang Jane (President, CMO) | Sale | 13,280 | 6.12 | 81,273 |
| 2023-04-04 | Huang Jane (President, CMO) | Option Ex | 37,500 | .00 | 0 |
| 2022-12-08 | Chardonnet Laurent (Chief Financial Officer) | Buy | 10,000 | 4.76 | 47,600 |
| 2022-06-01 | Chardonnet Laurent (Chief Financial Officer) | Buy | 10,000 | 4.23 | 42,300 |
| 2022-03-31 | Combs Andrew (EVP, Head of Chemistry) | Option Ex | 36,062 | 1.89 | 68,157 |
| 2021-12-15 | Morosini Deborah (EVP, Chief of Clinical Affairs) | Sale | 28,751 | 13.00 | 373,763 |
| 2021-12-15 | Morosini Deborah (EVP, Chief of Clinical Affairs) | Option Ex | 28,751 | 7.37 | 211,894 |
| 2021-12-14 | Combs Andrew (EVP, Head of Chemistry) | Buy | 4,000 | 11.60 | 46,400 |
| 2021-12-13 | Combs Andrew (EVP, Head of Chemistry) | Buy | 4,000 | 12.12 | 48,480 |
| 2021-11-16 | Morosini Deborah (EVP, Chief of Clinical Affairs) | Sale | 28,751 | 16.15 | 464,271 |
| 2021-11-16 | Morosini Deborah (EVP, Chief of Clinical Affairs) | Option Ex | 28,751 | 12.85 | 369,450 |
| 2021-10-05 | Mauro David J (Chief Medical Officer) | Sale | 15,000 | 31.21 | 468,120 |
| 2021-10-05 | Mauro David J (Chief Medical Officer) | Option Ex | 15,000 | 1.89 | 28,350 |
| 2021-09-07 | Mauro David J (Chief Medical Officer) | Sale | 15,000 | 36.87 | 553,110 |
| 2021-09-07 | Mauro David J (Chief Medical Officer) | Option Ex | 15,000 | 1.89 | 28,350 |
| 2021-09-02 | Pierce Christopher (EVP and Chief of Business Oper) | Sale | 17,000 | 41.44 | 704,412 |
| 2021-09-02 | Pierce Christopher (EVP and Chief of Business Oper) | Option Ex | 17,000 | 12.85 | 218,450 |
| 2021-08-27 | Scherle Peggy (Chief Scientific Officer) | Sale | 6,014 | 36.21 | 217,778 |
| 2021-08-27 | Scherle Peggy (Chief Scientific Officer) | Option Ex | 6,014 | 1.43 | 8,600 |
| 2021-08-26 | Scherle Peggy (Chief Scientific Officer) | Sale | 1,700 | 35.19 | 59,819 |
| 2021-08-26 | Scherle Peggy (Chief Scientific Officer) | Option Ex | 1,700 | 1.43 | 2,431 |
| 2021-08-25 | Piper Brian (Chief Financial Officer) | Sale | 8,333 | 33.33 | 277,772 |
| 2021-08-25 | Piper Brian (Chief Financial Officer) | Option Ex | 8,333 | 1.89 | 15,749 |
| 2021-08-13 | Scherle Peggy (Chief Scientific Officer) | Sale | 2,286 | 35.07 | 80,160 |
| 2021-08-13 | Scherle Peggy (Chief Scientific Officer) | Option Ex | 2,286 | 1.66 | 3,794 |
| 2021-08-05 | Mauro David J (Chief Medical Officer) | Sale | 15,000 | 31.43 | 471,510 |
| 2021-08-05 | Mauro David J (Chief Medical Officer) | Option Ex | 15,000 | 1.89 | 28,350 |
| 2021-07-27 | Scherle Peggy (Chief Scientific Officer) | Sale | 20,000 | 35.77 | 715,360 |
| 2021-07-27 | Scherle Peggy (Chief Scientific Officer) | Option Ex | 20,000 | 1.43 | 28,600 |
| 2021-07-06 | Mauro David J (Chief Medical Officer) | Sale | 15,000 | 28.05 | 420,720 |
| 2021-07-06 | Mauro David J (Chief Medical Officer) | Option Ex | 15,000 | 1.89 | 28,350 |
| 2021-06-07 | Mauro David J (Chief Medical Officer) | Sale | 15,000 | 31.57 | 473,535 |
| 2021-06-07 | Mauro David J (Chief Medical Officer) | Option Ex | 15,000 | 1.89 | 28,350 |
| 2021-05-25 | Piper Brian (Chief Financial Officer) | Sale | 8,333 | 34.79 | 289,938 |
| 2021-05-25 | Piper Brian (Chief Financial Officer) | Option Ex | 8,333 | 1.89 | 15,749 |
| 2021-05-07 | Scherle Peggy (Chief Scientific Officer) | Sale | 10,000 | 41.09 | 410,950 |
| 2021-05-07 | Scherle Peggy (Chief Scientific Officer) | Option Ex | 10,000 | 1.43 | 14,300 |
| 2021-05-05 | Mauro David J (Chief Medical Officer) | Sale | 15,000 | 40.24 | 603,600 |
| 2021-05-05 | Mauro David J (Chief Medical Officer) | Option Ex | 15,000 | 1.89 | 28,350 |
| 2021-04-29 | Morosini Deborah (EVP, Chief of Clinical Affairs) | Sale | 3,223 | 40.29 | 129,854 |
| 2021-04-29 | Morosini Deborah (EVP, Chief of Clinical Affairs) | Option Ex | 3,223 | 1.89 | 6,091 |
| 2021-04-27 | Mauro David J (Chief Medical Officer) | Sale | 25,000 | 35.48 | 887,100 |
| 2021-04-27 | Mauro David J (Chief Medical Officer) | Option Ex | 25,000 | 1.89 | 47,250 |
| 2021-04-19 | Mauro David J (Chief Medical Officer) | Sale | 25,000 | 31.05 | 776,150 |
| 2021-04-19 | Mauro David J (Chief Medical Officer) | Option Ex | 25,000 | 1.89 | 47,250 |
| 2021-04-08 | Scherle Peggy (Chief Scientific Officer) | Sale | 4,630 | 38.31 | 177,366 |
| 2021-04-08 | Pierce Christopher (EVP and Chief of Business Oper) | Sale | 200 | 40.00 | 8,000 |
| 2021-04-08 | Morosini Deborah (EVP, Chief of Clinical Affairs) | Sale | 100 | 40.00 | 4,000 |
| 2021-04-08 | Morosini Deborah (EVP, Chief of Clinical Affairs) | Option Ex | 100 | 1.89 | 189 |
| 2021-04-08 | Mauro David J (Chief Medical Officer) | Sale | 9,617 | 38.35 | 368,860 |
| 2021-04-08 | Mauro David J (Chief Medical Officer) | Option Ex | 9,617 | 1.89 | 18,176 |
| 2021-04-07 | Scherle Peggy (Chief Scientific Officer) | Sale | 15,370 | 39.65 | 609,389 |
| 2021-04-07 | Pierce Christopher (EVP and Chief of Business Oper) | Sale | 828 | 40.08 | 33,188 |
| 2021-04-07 | Mauro David J (Chief Medical Officer) | Sale | 15,383 | 39.36 | 605,428 |
| 2021-04-07 | Mauro David J (Chief Medical Officer) | Option Ex | 15,383 | 1.89 | 29,073 |
| 2021-01-27 | Baker Julian (Director) | Option Ex | 10,376 | 12.85 | 133,331 |
| 2020-09-29 | Combs Andrew (EVP, Head of Chemistry) | Buy | 1,000 | 19.00 | 19,000 |
| 2020-09-29 | Pierce Christopher (EVP and Chief of Business Oper) | Buy | 3,750 | 19.00 | 71,250 |
| 2020-09-29 | Morosini Deborah (EVP, Chief of Clinical Affairs) | Buy | 444 | 19.00 | 8,436 |
| 2020-09-29 | Dier Mardi (Director) | Buy | 10,000 | 19.00 | 190,000 |
| 2020-09-29 | Baker Julian (Director) | Buy | 1,578,947 | 19.00 | 29,999,993 |
| 2020-09-25 | Bonita David P (Director) | Buy | 1,236,800 | 19.00 | 23,499,200 |
| 2020-09-25 | Orbimed Capital Llc (Director) | Buy | 1,236,800 | 19.00 | 23,499,200 |
Insider trading activities including stock purchases, stock sales, and option exercises of PRLD listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Prelude Therapeutics Inc (symbol PRLD, CIK number 1678660) see the Securities and Exchange Commission (SEC) website.